Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia

Status unconfirmed · Phase 2

Conditions studied: Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

In brief

RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia.

Key facts

Study ID

NCT00008164

Run by

Herbert Irving Comprehensive Cancer Center

People needed

30

Starts

1997-01-01

Last updated by the study team

2013-12-18

Who can join

Age: any, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.